Type 2 diabetes
Conditions
Interventions
Switch from DPP-4 inhibitors to oral semaglutide
Continue DPP-4 inhibitors
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) HbA1c 7.0-10.0% 2) BMI >= 18.5 kg/m2 3) patients who were treated with DPP-4 inhibitors at least for 12 weeks before enrollment without discontinuation for more than 1 week 4) written informed consent
Exclusion criteria
Exclusion criteria: 1) patients with type 2 diabetes who were treated with any GLP-1 receptor agonist 2) history of anaphylaxis of semaglutide 3) unstable retinopathy 4) severe hepatic dysfunction or renal dysfunction 5) severe ketosis, diabetic coma 6) severe infection, surgery, serious trauma 7) pregnancy 8) patients who are inadequate to enter this study due to the other reasons by physician's judgments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in HbA1c from baseline at 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) The change in the other blood and urinary tests 2) The change in weight, abdominal circumference, blood pressure and pulse 3) Adverse effects 4) The factors associated with improvement of HbA1c and secondary endpoints | — |
Countries
Japan
Contacts
Public ContactHiroshi Nomoto
Hokkaido University Hospital Department of Diabetes and Endocrinology
Outcome results
None listed